Company Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases.
It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy.
It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
| Country | United States |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 268 |
| CEO | Gaurav Shah |
Contact Details
Address: 9 Cedarbrook Drive Cranbury, New Jersey 08512 United States | |
| Phone | 609 659 8001 |
| Website | rocketpharma.com |
Stock Details
| Ticker Symbol | RCKT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001281895 |
| CUSIP Number | 77313F106 |
| ISIN Number | US77313F1066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gaurav D. Shah M.D. | Chief Executive Officer and Director |
| Kinnari Patel M.B.A., Pharm.D. | Head of Research & Development, President and Chief Operating Officer |
| Mayo Pujols | Chief Technical Officer |
| Jonathan Schwartz M.D. | Chief Medical and Gene Therapy Officer |
| Aaron Ondrey | Chief Financial Officer |
| Martin Louis Wilson J.D. | General Counsel, Chief Compliance Officer and Chief Corporate Officer |
| Kevin Giordano | Director of Corporate Communications |
| Isabel Carmona J.D. | Chief People Officer |
| Dr. Gayatri R. Rao J.D., M.D. | Senior Vice President of Clinical Safety and Chief Regulatory Officer |
| Raj Prabhakar M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 21, 2025 | 144 | Filing |
| Feb 21, 2025 | 144 | Filing |
| Feb 21, 2025 | 144 | Filing |
| Feb 21, 2025 | 144 | Filing |
| Feb 21, 2025 | 144 | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Jan 31, 2025 | 144 | Filing |
| Jan 28, 2025 | 8-K | Current Report |
| Jan 23, 2025 | 144 | Filing |
| Dec 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |